

3rd August, 2016

To, The Manager, Listing Department, National Stock Exchange of India Ltd. "Exchange Plaza", C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DISHMAN (ii) Series – EQ	To, Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 532526
---	--

SUB.: UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30/06/2016

REF.: DISCLOSURE UNDER REGULATION 30 AND REGULATION 33 SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sir,

As per Regulation 30 of SEBI (LODR) Regulations, 2015 we hereby inform that a Meeting of the Board of Directors of the Company was held today i.e. on Wednesday, 3rd August, 2016 which was commenced at 11:00 AM and concluded at 1.45 p.m. at 301, 3rd Floor, "Samudra Annexe", Nr. Klassic Gold Hotel, Off. C. G. Road, Navrangpura, Ahmedabad – 380 009, *inter alia*, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended on 30th June, 2016, prepared in terms of Regulation 33 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

At the said Board Meeting the said Unaudited Results were adopted and approved, which are attached herewith.

Kindly take this on your record.


Thanking you.

Yours faithfully,

For, Dishman Pharmaceuticals and Chemicals Limited


Shrima Dave
Compliance Officer

Encl.: As above



Dishman Pharmaceuticals and Chemicals Limited

Registered Office: Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad – 380 009 India.

Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198

Email: dishman@dishmangroup.com Web: www.dishmangroup.com

Government Recognised Export House

CIN NO L24230GJ1983PLC006329

DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED


CIN : L24230GJ1983PLC006329 Email ID : dishman@dishmangroup.com Web : www.dishmangroup.com


Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad-380 009 Phone No : 079-26443053 Fax No : 079-26420198


Part I : Statement of Unaudited Standalone / Consolidated Financial Results for the Quarter Ended 30-06-2016

(Rupees in Crores / in Ten Million)

Sr. No.	PARTICULARS	STANDALONE		CONSOLIDATED	
		For The Quarter ended 30-06-2016	For The Corresponding Quarter ended 30-06-2015	For The Quarter ended 30-06-2016	For The Corresponding Quarter ended 30-06-2015
		Unaudited	Unaudited	Unaudited	Unaudited
1	Income From Operations				
	a) Net sales/income from operations (Net of excise duty)	83.71	133.71	365.88	400.04
	b) Other Operating Income	7.34	3.77	9.52	4.00
	Total Income from operations (net)	91.05	137.48	375.40	404.04
2	Expenses				
	a) Cost of material consumed	31.64	48.72	36.47	105.12
	b) Purchase of stock-in-trade	0.06	-	0.06	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(8.16)	11.37	17.65	(19.06)
	d) Employee benefits expense	15.41	14.87	145.05	124.07
	e) Depreciation and amortisation expense	11.20	11.34	28.48	26.13
	f) Other Expenditure	18.97	22.34	73.99	88.18
	Total expenses	69.12	108.64	301.70	324.44
3	Profit / (Loss) from Operations before Other Income, finance costs and exceptional items (1-2)	21.93	28.84	73.70	79.60
4	Other Income	4.94	9.06	7.01	3.94
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	26.87	37.90	80.71	83.54
6	Finance costs	16.30	25.93	22.46	31.80
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	10.57	11.97	58.25	51.74
8	Exceptional Items	-	-	-	-
9	Profit/(Loss) from Ordinary Activities before tax (7+8)	10.57	11.97	58.25	51.74
10	Tax expense	2.15	4.18	12.74	11.72
11	Net Profit/(Loss) for the period (9-10)	8.42	7.79	45.51	40.02
12	Income from Associates	-	-	-	0.00
13	Minority Interest	-	-	-	-
14	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (11+12+13)	8.42	7.79	45.51	40.02
15	Other Comprehensive Income (Net of Tax)	-	0.64	-	0.64
16	Total Comprehensive Income (After Tax) (14+15)	8.42	8.43	45.51	40.66
17	Paid -up Equity Share Capital (Face Value of Rs 2/- per equity share)	32.28	16.14	32.28	16.14
18	Basic and Diluted EPS (of Rs. 2 each)	-	-	-	-
	i) Basic EPS (Not annualised)	0.52	0.48	2.82	2.48
	ii) Diluted EPS (Not annualised)	0.52	0.48	2.82	2.48
	See accompanying notes to the financial results				



Segment wise Revenue, Result and Capital Employed		CONSOLIDATED	
Sr. No	PARTICULARS	For The Quarter ended 30-06-2016	For The Corresponding Quarter ended 30-06-2015
		Unaudited	Unaudited
1	Segment Revenue		
	(a) CRAMS	257.62	251.88
	(b) Others	108.26	148.16
	Total	365.88	400.04
	Less: Inter-segment Revenue	-	-
	Net Sales /Income from Operation	365.88	400.04
2	Segment Results (Profit/(Loss) before tax and interest from each segment)		
	(a) CRAMS*	52.98	52.07
	(b) Others*	20.72	27.53
	Total	73.70	79.60
	Less: i) Interest	22.46	31.80
	ii) Other un-allocable expenditure net off un-allocable income	(7.01)	(3.93)
	Total Profit/(Loss) Before Tax	58.25	51.74
* Includes Forex (Loss) / Gain			
Segmental Capital Employed : As certain assets of the company including manufacturing facilities, development facilities and financial assets and liabilities are often deployed interchangeably across segment, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table			
Place: Ahmedabad Date: 3rd August, 2016		For and on behalf of the board  Arpit Vyas Managing Director and CFO	




Notes:

- 1 The financial results for the quarter ended June 30, 2016 have been reviewed by the Audit Committee of the Board and subsequently approved by the Board of Directors at its meeting held on August 3, 2016 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The standalone financial result for the quarter ended June 30, 2016 have been subjected to review by Joint Statutory Auditors of the Company.
- 2 The Company adopted Indian Accounting Standard ("Ind AS") from April 1, 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of IND AS 34.
- 3 The standalone financial results for the quarter ended June 30, 2015 and consolidated financial results for the quarter ended June 30, 2016 and June 30, 2015 have not been reviewed or audited and have been presented based on the information compiled by the Management after making the necessary adjustments to give a true and fair view of the results in accordance with Ind AS.
- 4 As per Indian Accounting Standard ("Ind AS") 108 - "Segment Reporting", segment information has been provided in Consolidated Financial Result.
- 5 As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, the Company has opted to publish only consolidated financial results. The stand-alone financial results are available for perusal on the Company's website as well as on the stock exchanges' websites as stated below:
www.dishmangroup.com, www.bseindia.com, and www.nseindia.com.

- 6 The business segments of the Company comprise the following

Segment	Description of the activity
CRAMS	Contract Research and Manufacturing Segment under long term supply agreements
OTHERS	Manufacturing of Bulk Drugs, Intermediates, Quats, Speciality Chemicals, Vitamin D3 analogue and Traded Goods

- 7 Consolidated financial results comprise the results of the parent Company, Dishman Pharmaceuticals and Chemicals Limited and its subsidiaries viz. Dishman Europe Limited., Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd., Dishman Switzerland Limited, Dishman Pharma Solutions AG, Switzerland, CARBOGEN AMCIS (Shanghai) Co. Ltd. [formerly known as Dishman Pharmaceuticals & Chemicals (Shanghai) Co. Ltd.], Shanghai Yiqian International Trade Co. Ltd., Innovative Ozone Services Inc. (IO3S), Dishman Netherlands B. V. (formerly known as "Pharma Syn B. V."), Cohecie Fine Chemicals B.V. (formerly known as "Dishman Holland B.V."), Carbogen Amcis Ltd., U.K. (formerly known as "Synprotec DCR Ltd."), CARBOGEN AMCIS AG, Switzerland, Carbogen Amcis (India) Limited, Dishman Australasia Pty. Ltd., Dishman Care Ltd., CARBOGEN AMCIS SAS, Dishman Middle East (FZE), Dishman Japan Limited, Schutz Dishman Biotech Ltd. (72.33% holding by Dishman), and one associate company namely, Bhadr-Raj Holdings Pvt. Ltd. (40% holding by Dishman) as per relevant Accounting Standards as at June 30, 2016.




- 8 Reconciliation between financial results as previously reported (referred to as 'Previous GAAP') and Ind AS for quarter ended June 30, 2015 are as under:


Particulars	Rs. in crores	
	Quarter ended June 30, 2015	
	Standalone	Consolidated
Net profit as per Previous GAAP	8.01	37.76
Effect of change from operating lease to finance lease	-	0.94
Effect of Pre-operative expenses adjustment	-	1.03
Effect of deferred tax on Intra-group transaction	-	0.99
Impact due to recognition of asset retirement obligation	-	-0.56
Effect of foreign exchange loss now treated as revenue	-0.24	-0.24
Others	0.02	0.10
Net Profit/(Loss) for the period under Ind AS	7.79	40.02
Other Comprehensive Income	0.64	0.64
Total Comprehensive Income under Ind AS	8.43	40.66

- 9 Subsequent to 31st March, 2016, the Company has issued and allotted 8,06,97,136 equity shares of Rs.2/- each by utilization of General Reserve as fully paid-up bonus shares in the ratio of 1 (one) equity share for every 1 (one) equity share held to those shareholders whose names appear in the Register of Members / List of Beneficial owners as on the Record Date i.e. on May 3, 2016. With this allotment, the total issued and paid-up capital of the Company has increased to Rs.32,27,88,544/-.

On behalf of the Board of Directors

Place: Ahmedabad
Date: 3rd August, 2016




Arpit Vyas
Managing Director & CFO
DIN - 01540057